Community-acquired methicillin-resistant Staphylococcus aureus (MRSA): new issues for infection control

Int J Antimicrob Agents. 2007 Sep;30(3):210-2. doi: 10.1016/j.ijantimicag.2007.04.003. Epub 2007 Jun 12.


The emergence and clonal expansion of strains of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) have created new challenges with their entrance to hospitals. The increased virulence of CA-MRSA in concert with the depressed immunity of inpatients may cause added morbidity and mortality expected from healthcare-associated infections. Questions about changing prophylactic and empirical therapy as well as the use of intravenous immunoglobulin for life-threatening infections are addressed.

MeSH terms

  • Community-Acquired Infections / drug therapy*
  • Community-Acquired Infections / microbiology
  • Cross Infection / drug therapy
  • Cross Infection / microbiology
  • Humans
  • Infection Control
  • Leukocidins / genetics
  • Leukocidins / physiology
  • Methicillin Resistance*
  • Staphylococcal Infections / drug therapy*
  • Staphylococcal Infections / epidemiology
  • Staphylococcal Infections / microbiology
  • Staphylococcus aureus / drug effects*


  • Leukocidins